Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is showing strong Y/Y growth with Q4/25 revenue up 18% and a steady increase in customer additions and OUS sales growth. While gross margin of 65.9% was slightly below analyst estimates, EPS of ($0.17) exceeded expectations. The company's innovative OviTex portfolio is expected to continue driving sales growth as it targets various surgical procedures within soft-tissue reconstruction.

Bears say

TELA Bio is facing challenges in the market that is leading to a slowdown in its sales growth, which management attributes to their own strategic overhaul that is taking longer than anticipated to have an impact. The recent updates and changes to the company's commercial team and go-to-market strategy have yet to fully materialize, and there is still a lot of work to be done in terms of execution. Additionally, with a significant portion of the sales force being newly hired and a new territory strategy in place, there is a risk of disruption and potential loss of surgeons to competitors. Given these factors, the company has significantly lowered its sales growth outlook and faces pressure to demonstrate its ability to execute and regain investor confidence.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.